Palbociclib and pembrolizumab for brain metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer (any type) OR breast cancer or melanoma that has spread to the brain.
- You have at least one brain tumor that is at least 1 cm wide and is growing (getting worse) despite previous treatments.
- You have not taken a CDK4/6 inhibitor (like palbociclib) before.
- You have a tumor tissue sample available from a prior biopsy or surgery for genetic testing.
- You are generally healthy enough to be up and about (ECOG performance status 0-2), and your kidney, liver, and blood cell counts are within the study's normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Hear when a new Metastatic Malignant Neoplasm to Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.